Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity.

TL;DR: The functions and characteristics of SARS-CoV-2 NSPs that confer host immune evasion are summarized and the related potential therapeutic strategies for controlling the COVID-19 pandemic are discussed.

TL;DR: In this article , the authors discuss the emerging variants of SARS-CoV-2, notable mutations in the viral genome, the possible impact of these mutations on detection, disease presentation, and management as well as the recent findings in the mechanisms that underlie virus-host interaction.

TL;DR: In this paper , the SARS-CoV-2 S1 and S2 subunit proteins are discussed and the likely challenges that could limit the S 2 subunit from inducing robust immune responses and the promising approaches to increase its immunogenicity.

TL;DR: In this article , the authors sequenced 330 SARS-CoV-2 genomes during the sixth wave of the COVID pandemic in Iran and compared them with five previous waves, for identifying SARS•CoV•2 variants, the genomic behavior of the virus, and understanding its characteristics.

TL;DR: Characteristics of patients who died were in line with the MuLBSTA score, an early warning model for predicting mortality in viral pneumonia, and further investigation is needed to explore the applicability of the Mu LBSTA scores in predicting the risk of mortality in 2019-nCoV infection.

TL;DR: Identification and characterization of a new coronavirus (2019-nCoV), which caused an epidemic of acute respiratory syndrome in humans in Wuhan, China, and it is shown that this virus belongs to the species of SARSr-CoV, indicates that the virus is related to a bat coronav virus.

TL;DR: It is demonstrated that SARS-CoV-2 uses the SARS -CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming, and it is shown that the sera from convalescent SARS patients cross-neutralized Sars-2-S-driven entry.

TL;DR: The authors show that this protein binds at least 10 times more tightly than the corresponding spike protein of severe acute respiratory syndrome (SARS)–CoV to their common host cell receptor, and test several published SARS-CoV RBD-specific monoclonal antibodies found that they do not have appreciable binding to 2019-nCoV S, suggesting that antibody cross-reactivity may be limited between the two RBDs.